US Stock MarketDetailed Quotes
LIPO Lipella Pharmaceuticals
- 2.630
- +0.210+8.68%
Close Nov 22 16:00 ET
- 2.630
- 0.0000.00%
Post 20:02 ET
3.18MMarket Cap-613P/E (TTM)
2.700High2.420Low81.85KVolume2.420Open2.420Pre Close209.10KTurnover10.41%Turnover RatioLossP/E (Static)1.21MShares12.00052wk High2.18P/B2.07MFloat Cap2.21052wk Low--Dividend TTM786.30KShs Float61.760Historical High--Div YieldTTM11.57%Amplitude2.210Historical Low2.554Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Lipella Pharmaceuticals Stock Forum
Lipella's LP-310 OLP Treatment Advances in Phase 2a Trial with Promising Safety Data | LIPO Stock News
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform
Lipella Pharmaceuticals (Nasdaq: LIPO) announced the issuance of U.S. Patent No. 12,138,345 for its proprietary liposomal drug delivery platform. The patent, titled 'Delivery of Agents Using Metastable Liposomes,' extends market exclusivity for the company's lead clinical assets, LP-10and LP-310, currently in Phase 2 trials. LP-10 is a li...
Lipella Pharmaceuticals Will Be Issued U.S. Patent Number 12,138,345 Tomorrow Titled "DELIVERY OF AGENTS USING METASTABLE LIPOSOMES (FOR THE TREATMENT OF BLADDER CONDITIONS
No comment yet